Back to top
more

Teladoc Health (TDOC)

(Delayed Data from NYSE)

$7.17 USD

7.17
8,648,213

+0.07 (0.99%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $7.18 +0.01 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (172 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Teladoc (TDOC) Gained But Lagged the Market Today

by Zacks Equity Research

In the closing of the recent trading day, Teladoc (TDOC) stood at $7.17, denoting a +0.99% change from the preceding trading day.

Masimo's (MASI) W1 Watch Gains FDA Nod for SafetyNet Connectivity

by Zacks Equity Research

The latest FDA clearance of Masimo's (MASI) W1 medical watch is likely to provide a continuous and accurate view of patients' health data.

Debanjana Dey headshot

Hims & Hers (HIMS) Gains 45.8% in Three Months: What's Next?

by Debanjana Dey

Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

Teladoc Health (TDOC) Shares Down 8.9% Despite Q2 Earnings Beat

by Zacks Equity Research

Teladoc Health (TDOC) expects revenue growth in the Integrated Care segment to be within low to mid-single-digit growth in 2024, on a year-over-year basis.

Teladoc (TDOC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Teladoc (TDOC) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Teladoc (TDOC) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Teladoc (TDOC) delivered earnings and revenue surprises of 22.22% and 1.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Can Teladoc (TDOC) Q2 Earnings Navigate BetterHelp Profit Woes?

by Zacks Equity Research

Teladoc's (TDOC) second-quarter results are likely to reflect lower advertising and marketing expenses.

Countdown to Teladoc (TDOC) Q2 Earnings: Wall Street Forecasts for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Teladoc (TDOC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

Teladoc (TDOC) Ascends While Market Falls: Some Facts to Note

by Zacks Equity Research

Teladoc (TDOC) closed the most recent trading day at $9.30, moving +1.2% from the previous trading session.

Teladoc (TDOC) Ascends But Remains Behind Market: Some Facts to Note

by Zacks Equity Research

Teladoc (TDOC) closed the most recent trading day at $9.39, moving +0.21% from the previous trading session.

Debanjana Dey headshot

Hims & Hers (HIMS) Gains 37.7% in Three Months: What's Next?

by Debanjana Dey

Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

Teladoc (TDOC) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

Teladoc (TDOC) closed at $10.14 in the latest trading session, marking a -0.1% move from the prior day.

Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7%

by Zacks Equity Research

AI can help Teladoc (TDOC) to streamline healthcare delivery, making it more efficient and scalable.

Teladoc (TDOC) Soars 6.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Teladoc (TDOC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Teladoc (TDOC) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Teladoc (TDOC) concluded the recent trading session at $10.11, signifying a +1.1% move from its prior day's close.

Teladoc (TDOC) Rises Yet Lags Behind Market: Some Facts Worth Knowing

by Zacks Equity Research

Teladoc (TDOC) concluded the recent trading session at $10.66, signifying a +0.19% move from its prior day's close.

Teladoc (TDOC) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

In the most recent trading session, Teladoc (TDOC) closed at $10.87, indicating a -1.9% shift from the previous trading day.

Elevance Health (ELV) Stock Jumps 6.1%: Will It Continue to Soar?

by Zacks Equity Research

Elevance Health (ELV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Teladoc (TDOC) Registers a Bigger Fall Than the Market: Important Facts to Note

by Zacks Equity Research

In the closing of the recent trading day, Teladoc (TDOC) stood at $11.15, denoting a -1.85% change from the preceding trading day.

Here is What to Know Beyond Why Teladoc Health, Inc. (TDOC) is a Trending Stock

by Zacks Equity Research

Teladoc (TDOC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Teladoc Health (TDOC) Q1 Loss Widens on Decline in Visits

by Zacks Equity Research

Teladoc Health's (TDOC) Q1 results suffer from weak contributions from the BetterHelp unit. Management expects U.S. Integrated Care Members of 92-94 million for 2024, up from the prior mentioned 90-92 million.

Teladoc (TDOC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Teladoc (TDOC) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Teladoc (TDOC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Teladoc (TDOC) delivered earnings and revenue surprises of -4.26% and 1.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?

by Zacks Equity Research

Teladoc's (TDOC) first-quarter results are expected to have benefited from higher visits. However, high costs might have partially offset the positives.

Analysts Estimate Teladoc (TDOC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Teladoc (TDOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.